AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6210661 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous mezlocillin (16 g/day)
Number of subjects: 126
Study 6210661 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ampicillin (8 g/day)
Number of subjects: 126
Study 31232934 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 56
Study 31232934 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal tube (ETT)
Number of subjects: 56
Study 29282145 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental parenteral nutrition during neoadjuvant chemotherapy (NACT)
Number of subjects: 150
Study 29282145 — intervention group
Group type: COMPARATOR
Intervention: Standard care without supplemental parenteral nutrition
Number of subjects: 150
Study 25661664 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline glycaemic variability measures (GV) including standard deviation (SD), mean amplitude of glycaemic excursions (MAGE), mean absolute glucose (MAG), coefficient of variation (CV), high blood glucose index (HBGI), low blood glucose index (LBGI)
Number of subjects: 1699
Study 25661664 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline glycaemic variability measures (GV)
Number of subjects: 1699
Study 24300559 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystoscopy
Number of subjects: 109
Study 23046226 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding education program
Number of subjects: 60
Study 23046226 — intervention group
Group type: COMPARATOR
Intervention: Control program
Number of subjects: 60
Study 18838420 — intervention group
Group type: EXPERIMENTAL
Intervention: New Zealand candidate vaccine (epidemic strain NZ98/254, B:4:P1.7b,4)
Number of subjects: 296
Study 18838420 — intervention group
Group type: COMPARATOR
Intervention: Meningococcal C conjugate vaccine
Number of subjects: 296
Study 17559380 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg rabeprazole
Number of subjects: 164
Study 17559380 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg rabeprazole
Number of subjects: 164
Study 15449753 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (1 mg/kg)
Number of subjects: 30
Study 15449753 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (5 microg/kg)
Number of subjects: 30
Study 16584366 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot water immersion (45 degrees C)
Number of subjects: 96
Study 16584366 — intervention group
Group type: COMPARATOR
Intervention: Ice pack application
Number of subjects: 96
Study 10509376 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (DZP) 5.0 mg p.o.
Number of subjects: 2
Study 10509376 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 2
Study 8604671 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral riboflavin (20 mg)
Number of subjects: 9
Study 8604671 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral riboflavin (40 mg)
Number of subjects: 9
Study 8604671 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral riboflavin (60 mg)
Number of subjects: 9
Study 8604671 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous riboflavin (11.6 mg)
Number of subjects: 9
Study 8604671 — intervention group
Group type: COMPARATOR
Intervention: Control period (no riboflavin administration)
Number of subjects: 9
Study 1824584 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 955
Study 1824584 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 955
Study 1824584 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 955
Study 1824584 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 955
Study 1824584 — intervention group
Group type: COMPARATOR
Intervention: Volatile anesthetics (general category)
Number of subjects: 955
Study 1824584 — intervention group
Group type: COMPARATOR
Intervention: All anesthetics
Number of subjects: 955
Study 6093270 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagenase
Number of subjects: 30
Study 6093270 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 30
Study 29405872 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Taping (KT)
Number of subjects: 38
Study 29405872 — intervention group
Group type: COMPARATOR
Intervention: Placebo Taping
Number of subjects: 38
Study 30205602 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 g cooked whole egg (CWE)
Number of subjects: 33
Study 30205602 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 g cooked whole egg (CWE)
Number of subjects: 33
Study 30205602 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 g cooked whole egg (CWE)
Number of subjects: 33
Study 30205602 — intervention group
Group type: COMPARATOR
Intervention: No egg
Number of subjects: 33
Study 27187457 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-protein diet (HP: 38% carbohydrate, 30% protein, 29% fat)
Number of subjects: 61
Study 27187457 — intervention group
Group type: COMPARATOR
Intervention: Higher-carbohydrate diet (HC: 53% carbohydrate, 21% protein, 23% fat)
Number of subjects: 61
Study 24779241 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg mifepristone
Number of subjects: 60
Study 24779241 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg mifepristone
Number of subjects: 60
Study 24779241 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg mifepristone
Number of subjects: 60
Study 24779241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 22416059 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer led parenting intervention (Empowering parents, empowering communities), 8 weeks, 2 hours each week
Number of subjects: 116
Study 22416059 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 116
Study 22416059 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer led parenting intervention
Number of subjects: 116
Study 19561542 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab therapy (3-dose induction regimen)
Number of subjects: 31
Study 17468647 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV7 booster at 15 months
Number of subjects: 331
Study 17468647 — intervention group
Group type: COMPARATOR
Intervention: PCV7 booster at 18 months
Number of subjects: 331
Study 15883741 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim 300 microg once daily
Number of subjects: 59
Study 15883741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 12517615 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position for 3 days after the operation (Group A)
Number of subjects: 46
Study 12517615 — intervention group
Group type: COMPARATOR
Intervention: Sitting position on the day after the operation (Group B)
Number of subjects: 46
Study 9501815 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurolytic coeliac plexus block (NCPB)
Number of subjects: 24
Study 9501815 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological therapy
Number of subjects: 24
Study 7711146 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose/xylitol mixture (1:1) (C II)
Number of subjects: 23
Study 7711146 — intervention group
Group type: COMPARATOR
Intervention: Glucose (C I)
Number of subjects: 23
Study 7711146 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (C III)
Number of subjects: 23
Study 30720599 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture intervention
Number of subjects: 116
Study 30720599 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 116
Study 28348195 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 hours per week Early Start Denver Model (ESDM) intervention by trained therapists (10 hours in center, 2 hours in natural environment)
Number of subjects: 180
Study 28348195 — intervention group
Group type: COMPARATOR
Intervention: Care available in the community (Control)
Number of subjects: 180
Study 28348195 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 hours per week Early Start Denver Model (ESDM) intervention
Number of subjects: 180
Study 25061714 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC therapy + vitamin D3 (Cholecalciferol) 15,000 IU/week
Number of subjects: 101
Study 25061714 — intervention group
Group type: COMPARATOR
Intervention: SOC therapy (Peg-interferon alfa-2b plus ribavirin)
Number of subjects: 101
Study 23398616 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured communication intervention
Number of subjects: 52
Study 23398616 — intervention group
Group type: COMPARATOR
Intervention: No structured communication intervention
Number of subjects: 52
Study 21705959 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation (0.32% of total fatty acids as DHA)
Number of subjects: 122
Study 21705959 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation (0.64% of total fatty acids as DHA)
Number of subjects: 122
Study 21705959 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation (0.96% of total fatty acids as DHA)
Number of subjects: 122
Study 21705959 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation (0.32% and 0.64% of total fatty acids as DHA)
Number of subjects: 122
Study 21705959 — intervention group
Group type: COMPARATOR
Intervention: Unsupplemented formula (0.00% of total fatty acids as DHA)
Number of subjects: 122
Study 19910316 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive cardiac output monitoring (NICOM)
Number of subjects: 47
Study 16968576 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily ofloxacin otic solution (0.3%)
Number of subjects: 278
Study 16968576 — intervention group
Group type: COMPARATOR
Intervention: Neomycin sulfate/polymyxin B sulfate/hydrocortisone otic suspension (four times daily)
Number of subjects: 278
Study 15282009 — intervention group
Group type: EXPERIMENTAL
Intervention: Epi-No birth training device
Number of subjects: 48
Study 15282009 — intervention group
Group type: COMPARATOR
Intervention: Control group (primigravid non-users)
Number of subjects: 48
Study 11282262 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitafloxacin (400 mg once daily)
Number of subjects: 69
Study 11282262 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin (500 mg three times daily)
Number of subjects: 69
Study 11282262 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 69
Study 9248383 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing maneuvers (suctioning, bathing and turning)
Number of subjects: 22
Study 8505664 — intervention group
Group type: EXPERIMENTAL
Intervention: High calcium diet (total calcium intake of 2200 mg/d)
Number of subjects: 13
Study 8505664 — intervention group
Group type: COMPARATOR
Intervention: Low calcium diet (240 mg Ca/d)
Number of subjects: 13
Study 3425265 — intervention group
Group type: EXPERIMENTAL
Intervention: PVP-iodine eye-drops as a pre-operative disinfectant
Number of subjects: 4111
Study 3425265 — intervention group
Group type: COMPARATOR
Intervention: 2.5% iodine on the skin only (control group)
Number of subjects: 4111
Study 30404973 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive CR group (n=18; CR participation ≥twice/week, daily PA ≥9,000 steps)
Number of subjects: 32
Study 30404973 — intervention group
Group type: COMPARATOR
Intervention: Standard CR group (n=14; CR participation ≥once/2weeks, daily PA ≥6,000 steps)
Number of subjects: 32
Study 30404973 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients classified by median PA (7,000 steps)
Number of subjects: 32
Study 30404973 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with higher PA (≥7,000 steps)
Number of subjects: 32
Study 26884352 — intervention group
Group type: EXPERIMENTAL
Intervention: estradiol valerate (E2V)
Number of subjects: 200
Study 26884352 — intervention group
Group type: EXPERIMENTAL
Intervention: conjugated equine estrogen (CEE)
Number of subjects: 200
Study 26884352 — intervention group
Group type: EXPERIMENTAL
Intervention: isoflavones
Number of subjects: 200
Study 26884352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 25440306 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based therapy (FBT)
Number of subjects: 79
Study 25440306 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent-focused individual therapy (AFT)
Number of subjects: 79
Study 25440306 — intervention group
Group type: COMPARATOR
Intervention: Both treatments (FBT and AFT)
Number of subjects: 79
Study 22796132 — intervention group
Group type: COMPARATOR
Intervention: 40 mg esomeprazole twice daily + aspirin placebo once daily (arm A; n = 30)
Number of subjects: 114
Study 22796132 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg esomeprazole twice daily + 81 mg aspirin once daily (arm B; n = 47)
Number of subjects: 114
Study 22796132 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg esomeprazole twice daily + 325 mg aspirin once daily (arm C; n = 45)
Number of subjects: 114
Study 20506932 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized bioterrorism education and training program
Number of subjects: 0
Study 20506932 — intervention group
Group type: COMPARATOR
Intervention: Standard bioterrorism education and training program
Number of subjects: 0
Study 18559649 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisone 10 mg
Number of subjects: 0
Study 18559649 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisone 20 mg
Number of subjects: 0
Study 18559649 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisone 30 mg
Number of subjects: 0
Study 18559649 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisone 40 mg
Number of subjects: 0
Study 18559649 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisone 80 mg (single dose)
Number of subjects: 0
Study 18559649 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisone 40 mg (multiple doses for 3 days)
Number of subjects: 0
Study 18559649 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisone 80 mg (multiple doses for 3 days)
Number of subjects: 0
Study 18559649 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisone (ex vivo pharmacodynamic activity)
Number of subjects: 0
Study 18559649 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisone (bioassay)
Number of subjects: 0
Study 15679068 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pamidronate, 3 mg/kg over 3 days every 4 months
Number of subjects: 12
Study 15679068 — intervention group
Group type: COMPARATOR
Intervention: Oral alendronate 1 mg/kg, from a minimum of 10 mg to a maximum of 20 mg daily
Number of subjects: 12
Study 15679068 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pamidronate
Number of subjects: 12
Study 15679068 — intervention group
Group type: COMPARATOR
Intervention: Oral alendronate
Number of subjects: 12
Study 12826145 — intervention group
Group type: EXPERIMENTAL
Intervention: Gengraf (generic formulation of cyclosporine)
Number of subjects: 41
Study 10543669 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmastectomy radiotherapy (n=1538)
Number of subjects: 3083
Study 10543669 — intervention group
Group type: COMPARATOR
Intervention: No radiotherapy (n=1545)
Number of subjects: 3083
Study 7573711 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-day treatment with 6 mg of DEC/kg of body weight (group 1)
Number of subjects: 0
Study 7573711 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of 6 mg of DEC/kg of body weight at an interval of six months (group 2)
Number of subjects: 0
Study 7573711 — intervention group
Group type: COMPARATOR
Intervention: Community level after group 1 treatment
Number of subjects: 0
Study 7573711 — intervention group
Group type: COMPARATOR
Intervention: Community level after group 2 treatment
Number of subjects: 0
Study 2044527 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascending order of exercise intensities (65%, 75%, 85%, 95% VO2 max)
Number of subjects: 13
Study 2044527 — intervention group
Group type: EXPERIMENTAL
Intervention: Descending order of exercise intensities (65%, 75%, 85%, 95% VO2 max)
Number of subjects: 13
Study 2044527 — intervention group
Group type: EXPERIMENTAL
Intervention: Random order of exercise intensities (65%, 75%, 85%, 95% VO2 max)
Number of subjects: 13
Study 2044527 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise at standard intensity (65% or 95% VO2 max) before and after sauna bath
Number of subjects: 13
Study 6810734 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 5
Study 6810734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 31511706 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor Relearning Programme
Number of subjects: 66
Study 31511706 — intervention group
Group type: COMPARATOR
Intervention: Mirror therapy
Number of subjects: 66
Study 29130624 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced bleomycin dose (10,000 IU/m2)
Number of subjects: 28
Study 29130624 — intervention group
Group type: COMPARATOR
Intervention: Standard bleomycin dose (15,000 IU/m2)
Number of subjects: 28
Study 26969631 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based transitional palliative care (weekly home visits/telephone calls for 4 weeks, then monthly follow-up)
Number of subjects: 84
Study 26969631 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based transitional palliative care
Number of subjects: 84
Study 26969631 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 84
Study 25224756 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) intervention
Number of subjects: 60
Study 25224756 — intervention group
Group type: EXPERIMENTAL
Intervention: PMTCT Option B
Number of subjects: 60
Study 25224756 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (Control)
Number of subjects: 60
Study 22869826 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy media use intervention (replacing violent or age-inappropriate media with educational content)
Number of subjects: 565
Study 22869826 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 565
Study 20163429 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walk test (6MWT)
Number of subjects: 126
Study 20163429 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed Up and Go (TUG) test
Number of subjects: 126
Study 20163429 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Mobility Scale (FMS) scores
Number of subjects: 126
Study 20163429 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple regression analysis
Number of subjects: 126
Study 18275370 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed individuals who attempted suicide
Number of subjects: 0
Study 18275370 — intervention group
Group type: COMPARATOR
Intervention: Depressed individuals who did not attempt suicide
Number of subjects: 0
Study 16084255 — intervention group
Group type: EXPERIMENTAL
Intervention: Management with PAC (n=519)
Number of subjects: 1041
Study 16084255 — intervention group
Group type: COMPARATOR
Intervention: Management without PAC (n=522)
Number of subjects: 1041
Study 11839628 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAM10 protein expression during AF
Number of subjects: 30
Study 11839628 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAM15 protein expression during AF
Number of subjects: 30
Study 11839628 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAM15 mRNA expression during AF
Number of subjects: 30
Study 11839628 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAM/integrin ratios in patients with AF
Number of subjects: 30
Study 10077706 — intervention group
Group type: EXPERIMENTAL
Intervention: Free supplementary insurance for complementary medicine
Number of subjects: 7500
Study 10077706 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementary insurance)
Number of subjects: 7500
Study 7574745 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous arterial infusion of CDDP (10 mg/body) and 5-FU (250 mg/body) for 5 days, with 4 courses administered
Number of subjects: 22
Study 7574745 — intervention group
Group type: COMPARATOR
Intervention: Continuous arterial infusion of CDDP and 5-FU for 24 hours
Number of subjects: 22
Study 2076713 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg daily)
Number of subjects: 0
Study 2076713 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (25 mg daily)
Number of subjects: 0
Study 2076713 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril and Hydrochlorothiazide (combined)
Number of subjects: 0
Study 2076713 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril alone
Number of subjects: 0
Study 6818864 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 0
Study 6818864 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 0
Study 31914241 — intervention group
Group type: EXPERIMENTAL
Intervention: Luspatercept (1.0 up to 1.75 mg/kg, subcutaneously every 3 weeks)
Number of subjects: 229
Study 31914241 — intervention group
Group type: COMPARATOR
Intervention: Placebo (subcutaneously every 3 weeks)
Number of subjects: 229
Study 31914241 — intervention group
Group type: EXPERIMENTAL
Intervention: Luspatercept
Number of subjects: 229
Study 31914241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study 29182039 — intervention group
Group type: EXPERIMENTAL
Intervention: Goishi tea polyphenols (122 mg of polyphenols daily)
Number of subjects: 77
Study 29182039 — intervention group
Group type: COMPARATOR
Intervention: Placebo (12.2 mg of polyphenols daily)
Number of subjects: 77
Study 27129137 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-gauge needle with a core trap (ProCore)
Number of subjects: 214
Study 27129137 — intervention group
Group type: COMPARATOR
Intervention: Standard 25-gauge needle
Number of subjects: 214
Study 24722960 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month telephone-based health coaching intervention (11 sessions using acceptance and commitment therapy strategies)
Number of subjects: 410
Study 23579543 — intervention group
Group type: EXPERIMENTAL
Intervention: Billroth II reconstruction (n = 52)
Number of subjects: 101
Study 23579543 — intervention group
Group type: COMPARATOR
Intervention: Roux-en-Y reconstruction (n = 49)
Number of subjects: 101
Study 23579543 — intervention group
Group type: EXPERIMENTAL
Intervention: Billroth II reconstruction
Number of subjects: 101
Study 23579543 — intervention group
Group type: COMPARATOR
Intervention: Roux-en-Y reconstruction
Number of subjects: 101
Study 23579543 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with DGE
Number of subjects: 101